Cognitive Dysfunction
Conditions
Keywords
mild cognitive impairment
Brief summary
This study evaluates the effects of computerized cognitive training and cognitive training plus exercise training on different cognitive domains in mild cognitive impairment (MCI) patients. Patients will be randomized into the computerized training group, cognitive training plus exercise training group and the control group.
Detailed description
Mild cognitive impairment (MCI) is an early stage of Alzheimer Disease (AD). Increasing evidence has indicated that cognitive trainings improve cognition functions of MCI patients in multiple cognitive domains, making it a promising therapy for MCI. However, the effect of long-time training has not been widely explored. It is also necessary to evaluate the extent of its function in reducing the conversion rate from MCI to AD.
Interventions
BEHAVIORALOnline cognitive training
A variety of cognitive domains will be involved in the training including memory, calculation, attention, visuospatial and executive skills. The difficulty level of each game will be adjusted automatically according to patients' last training results so that patients' correction rate will be kept between 70% and 80%.
BEHAVIORALCognitive training plus physical exercise
Online cognitive training A variety of cognitive domains will be involved in the training including memory, calculation, attention, visuospatial and executive skills. The difficulty level of each game will be adjusted automatically according to patients' last training results so that patients' correction rate will be kept between 70% and 80%. Physical Exercise Tai Chi Training：a teacher will give two 60-min lessons per week. Participants will play Tai Chi in the lessons, following teacher's instruction.
Sponsors
RenJi Hospital
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Huashan Hospital
Ruijin Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Male or female, aged 50-85; * MCI diagnosed according to the National Institute on Aging-Alzheimer's Association (NIA-AA) workgroups\[1\]; * 24≤Mini-Mental State Examination (MMSE) ≤28； * The Hamilton Depression Scale/17-item (HAMD) score ≤10; * Not on medication for dementia; * MRI T2 weighted image (T2WI) scan: aged ≤70 , Fazeca scale for White Matter lesions rating level≤1; \>70 years, white matter damage rating scale ≤2. The number of lacunar infarcts larger than 2 cm in diameter ≤2. No infarcts in hypothalamus, entorhinal cortex, para-hypothalamus, cortical and subcortical cavity infarction near gray matter nuclei. The medial temporal lobe atrophy (MTA) score: Grade II or above. * Accompanied by reliable caregivers (at least intensive contact of 4 days every week and 2 hours every day) who are expected to participate in the follow-up visits and provide useful information for scores of scales like ADCS-ADL; * Education level: primary school (grade 6) or above. * Expected good compliance with the therapy and follow-up. Each patient gives a written informed consent, and the study has been approved by Ruijin Hospital's ethical committees.
Exclusion criteria
* Cognitive decline caused by other diseases (cerebrovascular disease, central nervous system infections, Parkinson's disease, metabolic encephalopathy, intracranial space-occupying lesions, deficiency of folic acid/vitamin B12 and hypothyroidism); * Medical history of other neurological disorders (including stroke, Neuromyelitis optica, Parkinson's disease, epilepsy, etc.); * Psychiatric disorders defined by (Diagnostic and Statistical Manual of Mental Disorders) DSM-IV criteria; * Unstable or severe disease of heart, lung, liver, kidney or hematopoietic system; * History of alcohol or drug abuse; * Participation in other clinical trial less than 30 days before the screening of this study; * Inability to complete the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of AD | 12 months | The 3-year incidence of AD in each group will be compared. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Memory | 12 months | Memory will be assessed using the Auditory verbal learning test-Huashan version (AVLT-H). |
| Attention | 12 months | Attention will be evaluated by Trial Making Test (TMT). |
| Executive functions | 12 months | Executive functions will be evaluated by the Stroop task. |
| Language | 12 months | Language will be assessed by Boston naming test (30-item version). |
| The global cognitive function of MCI patients | 6 months | Alzheimer disease assessment scale (ADAS-Cog) will be used to assess the global cognitive performance of MCI patients |
| Activities of daily living | 6 months | Activities of daily living will be assessed by Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL). |
| Structural MRI | 12 months | Volume of hippocampus and other specific brain regions |
| Gut microbiota | 12 months | Number of genera and abundence of E.coli in feces and blood |
| Visual spatial ability and visual memory | 12 months | Visual spatial ability and visual memory will be evaluated by the Rey-Osterrieth complex figure test (CFT). |
Countries
China
Contacts
Primary ContactSheng-Di Chen
Outcome results
None listed